Meta-Analysis
Copyright ©The Author(s) 2023.
World J Diabetes. Aug 15, 2023; 14(8): 1289-1300
Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1289
Table 1 Characteristics of included studies for the risk of overall cause of death
Ref.
City
Country
Study period
Design
N
Therapy
DM (no metformin)
Number of events
DM (metformin)
Number of events
Chen et al[29], 2011TaichungTaiwanJune 2003 to July 2009Retro53RFA3218216
Bhat et al[25], 2014RochesterUnited StatesJanuary 2005 to June 2011Retro263No therapy2071335637
Jang et al[30], 2015SeoulKoreaMarch 2003 to December 2012Retro48RT2913195
Casadei Gardini et al[31], 2015MeldolaItalyMarch 2008 to August 2014Retro42Sorafenib1153122
Seo et al[32], 2016SeoulKoreaJanuary 2005 to December 2011Retro751HR218111533169
Chan et al[33], 2017TaipeiTaiwanJanuary 1995 to December 2011Retro4610HR297813351632612
7813No surgery5884385819291437
Casadei Gardini et al[24], 2017MeldolaItalyMay 2007 to September 2015Retro86Sorafenib34265245
Chung et al[34], 2018SeoulKoreaJanuary 2009 to December 2016Retro63Sorafenib + HR23234030
31Sorafenib + LT17141413
Luo et al[26], 2020NanchangChinaJanuary 2000 to December 2013Retro250HR1841296649
Cho et al[35], 2021KaohsiungTaiwanApril 2001 to June 2016Retro222HR861513626
Tangjarusritaratorn et al[36], 2021BangkokThailandJanuary 2006 to June 2014Prosp327Multiple therapies1658416260
Elsayed et al[37], 2021AtlantaUnited States2014-2018Retro40TARE218198
Hydes et al[38], 2022BirminghamUnited KingdomJanuary 2007 to March 2012Prosp287Multiple therapies1395814863
Total1488610028583048582582